GYL Financial Synergies LLC acquired a new position in Amgen, Inc. (NASDAQ:AMGN) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 2,297 shares of the medical research company’s stock, valued at approximately $447,000.
A number of other hedge funds have also modified their holdings of the stock. Blue Fin Capital Inc. grew its position in shares of Amgen by 10.0% in the 3rd quarter. Blue Fin Capital Inc. now owns 7,449 shares of the medical research company’s stock worth $1,544,000 after buying an additional 677 shares during the period. Vident Investment Advisory LLC grew its position in shares of Amgen by 135.5% in the 3rd quarter. Vident Investment Advisory LLC now owns 5,238 shares of the medical research company’s stock worth $1,086,000 after buying an additional 3,014 shares during the period. Cypress Capital Group grew its position in shares of Amgen by 4.1% in the 3rd quarter. Cypress Capital Group now owns 18,096 shares of the medical research company’s stock worth $3,751,000 after buying an additional 708 shares during the period. HRT Financial LLC grew its position in shares of Amgen by 137.7% in the 3rd quarter. HRT Financial LLC now owns 5,959 shares of the medical research company’s stock worth $1,235,000 after buying an additional 3,452 shares during the period. Finally, Brown Brothers Harriman & Co. grew its position in shares of Amgen by 8.6% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 7,628 shares of the medical research company’s stock worth $1,581,000 after buying an additional 603 shares during the period. 79.18% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ AMGN opened at $188.05 on Wednesday. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The stock has a market cap of $117.77 billion, a PE ratio of 13.06, a P/E/G ratio of 2.34 and a beta of 1.21. Amgen, Inc. has a 52-week low of $165.22 and a 52-week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same quarter last year, the firm posted $2.89 EPS. On average, equities research analysts forecast that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is presently 40.28%.
A number of analysts have recently weighed in on the stock. Mizuho set a $208.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, April 12th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. BidaskClub downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Royal Bank of Canada reaffirmed a “neutral” rating and issued a target price on shares of Amgen in a research report on Monday, January 14th. Finally, Morgan Stanley reduced their target price on shares of Amgen from $213.00 to $212.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 19th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $209.11.
In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total transaction of $377,760.00. Following the sale, the director now owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 6,000 shares of company stock worth $1,144,120. Insiders own 0.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: “GYL Financial Synergies LLC Acquires New Holdings in Amgen, Inc. (AMGN)” was originally published by Macon Daily and is the property of of Macon Daily. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://macondaily.com/2019/04/17/gyl-financial-synergies-llc-acquires-new-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.